Liothyronine sustained-release

Drug Profile

Liothyronine sustained-release

Alternative Names: BCT-303; Liothyronine sodium; Sustained-release liothyronine sodium; Sustained-release T3; Thyromax; TriThroid

Latest Information Update: 21 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ITL Pharma
  • Developer IPE
  • Class Amino acids; Small molecules; Thyronines
  • Mechanism of Action Thyroid hormone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Hypothyroidism

Most Recent Events

  • 20 Feb 2017 ITL Pharma has patent protection for TriThroid® in USA
  • 18 Apr 2016 Phase-II development is ongoing in USA
  • 01 Jul 2014 IPE completes a phase II trial in Hypothyroidism in USA (NCT01800617)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top